Ashish Kumar Sharma; Akash Sharma; Rita Kumari; Kunal Kishore; Divya Sharma; Bharthu Parthsarthi Srinivasan; Ashok Sharma; Santosh Kumar Singh; Samir Gaur; Vijay Singh Jatav; Prashant Sharma; Varnika Srivastava; Sneha Joshi; Megha Joshi; Prashant Kumar Dhakad; Davender Singh Kanawat; Akanksha Mishra; Anil Sharma; Dharmendra Singh; Ravinder Pal Singh; Himmat Singh Chawda; Rambir Singh; Sachin Kumar Raikwar; Muneem Kumar Kurmi; Pankaj Khatri; Ashutosh Agarwal; Arshee Munajjam

doi:10.7555/JBR.26.20110054

Advanced Search

Authors and Reviewers

PDF
Cite
Share

facebook

twitter

google

linkedin

Volume 26 Issue 3

May 2012

Turn off MathJax

Article Contents

Article Navigation > The Journal of Biomedical Research > 2012 > 26(3): 200-210

Ashish Kumar Sharma, Akash Sharma, Rita Kumari, Kunal Kishore, Divya Sharma, Bharthu Parthsarthi Srinivasan, Ashok Sharma, Santosh Kumar Singh, Samir Gaur, Vijay Singh Jatav, Prashant Sharma, Varnika Srivastava, Sneha Joshi, Megha Joshi, Prashant Kumar Dhakad, Davender Singh Kanawat, Akanksha Mishra, Anil Sharma, Dharmendra Singh, Ravinder Pal Singh, Himmat Singh Chawda, Rambir Singh, Sachin Kumar Raikwar, Muneem Kumar Kurmi, Pankaj Khatri, Ashutosh Agarwal, Arshee Munajjam. Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats[J]. The Journal of Biomedical Research, 2012, 26(3): 200-210. doi: 10.7555/JBR.26.20110054

Citation:

Ashish Kumar Sharma, Akash Sharma, Rita Kumari, Kunal Kishore, Divya Sharma, Bharthu Parthsarthi Srinivasan, Ashok Sharma, Santosh Kumar Singh, Samir Gaur, Vijay Singh Jatav, Prashant Sharma, Varnika Srivastava, Sneha Joshi, Megha Joshi, Prashant Kumar Dhakad, Davender Singh Kanawat, Akanksha Mishra, Anil Sharma, Dharmendra Singh, Ravinder Pal Singh, Himmat Singh Chawda, Rambir Singh, Sachin Kumar Raikwar, Muneem Kumar Kurmi, Pankaj Khatri, Ashutosh Agarwal, Arshee Munajjam. Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats[J]. The Journal of Biomedical Research, 2012, 26(3): 200-210. doi: 10.7555/JBR.26.20110054

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats

doi: 10.7555/JBR.26.20110054

1.
Department of Pharmacology, Gyan Vihar School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Jaipur (Rajasthan) 302025, India
2.
Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences & Research, Pushpvihar, New Delhi 110017, India
3.
Department of Pharmacology, Kota Collage of Pharmacy, RIICO Industrial Area, Ranpur, Kota (Rajasthan), Pincode 302025, Ind

Received Date: 2011-05-09
Publish Date: 2012-06-05

Abstract

Diabetic neuropathies are a family of nerve disorders caused by diabetes. Symptoms of the disease include nerve palsy, mononeuropathy, mononeuropathy multiplex, diabetic amyotrophy, painful polyneuropathy, autonomic neuropathy, and thoracoabdominal neuropathy. In this study, type 2 diabetes in rats was induced with nicotinamide-streptozotocin. Drug treatment was initiated on the d 15, with the combination regimen of metformin, pioglitazone and glimipiride or metformin and sitagliptin or sitagliptin, amitriptyline and sitagliptin and led to significantly improved glycemic control, increased grip strength and paw jumping response on d 21, 28 and 35 (P < 0.001). Significant increases in blood protein levels and decreases in urinary protein levels were observed in the animals treated with the different regimens on d 21, 28 and 35 (P < 0.001). Combined treatment of streptozotocin and nicotinamide caused marked degeneration of nerve cells, while administration of metformin and sitagliptin showed tissue regeneration and no body weight gain. In conclusion, treatment with sitagliptin and sitagliptin combined with metformin or amitriptyline results in no body weight gain, but causes an increase in grip strength and pain sensitivity, exhibits neural protection, and reverses the alteration of biochemical parameters in rats with streptozotocin-nicotinamide induced type 2 diabetes.
- diabetic neuropathy,
- nicotinamide-streptozotocin,
- metformin,
- pioglitazone,
- glimipiride,
- sitagliptin,
- amitriptyline
References
Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(5135) PDF downloads(56) Cited by()

Proportional views

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats

doi: 10.7555/JBR.26.20110054

1. Department of Pharmacology, Gyan Vihar School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Jaipur (Rajasthan) 302025, India

2. Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences & Research, Pushpvihar, New Delhi 110017, India

3. Department of Pharmacology, Kota Collage of Pharmacy, RIICO Industrial Area, Ranpur, Kota (Rajasthan), Pincode 302025, Ind

Received Date: 2011-05-09
Publish Date: 2012-06-05

Key words:

Abstract: Diabetic neuropathies are a family of nerve disorders caused by diabetes. Symptoms of the disease include nerve palsy, mononeuropathy, mononeuropathy multiplex, diabetic amyotrophy, painful polyneuropathy, autonomic neuropathy, and thoracoabdominal neuropathy. In this study, type 2 diabetes in rats was induced with nicotinamide-streptozotocin. Drug treatment was initiated on the d 15, with the combination regimen of metformin, pioglitazone and glimipiride or metformin and sitagliptin or sitagliptin, amitriptyline and sitagliptin and led to significantly improved glycemic control, increased grip strength and paw jumping response on d 21, 28 and 35 (P < 0.001). Significant increases in blood protein levels and decreases in urinary protein levels were observed in the animals treated with the different regimens on d 21, 28 and 35 (P < 0.001). Combined treatment of streptozotocin and nicotinamide caused marked degeneration of nerve cells, while administration of metformin and sitagliptin showed tissue regeneration and no body weight gain. In conclusion, treatment with sitagliptin and sitagliptin combined with metformin or amitriptyline results in no body weight gain, but causes an increase in grip strength and pain sensitivity, exhibits neural protection, and reverses the alteration of biochemical parameters in rats with streptozotocin-nicotinamide induced type 2 diabetes.

Citation:

Ashish Kumar Sharma, Akash Sharma, Rita Kumari, Kunal Kishore, Divya Sharma, Bharthu Parthsarthi Srinivasan, Ashok Sharma, Santosh Kumar Singh, Samir Gaur, Vijay Singh Jatav, Prashant Sharma, Varnika Srivastava, Sneha Joshi, Megha Joshi, Prashant Kumar Dhakad, Davender Singh Kanawat, Akanksha Mishra, Anil Sharma, Dharmendra Singh, Ravinder Pal Singh, Himmat Singh Chawda, Rambir Singh, Sachin Kumar Raikwar, Muneem Kumar Kurmi, Pankaj Khatri, Ashutosh Agarwal, Arshee Munajjam. Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats[J]. The Journal of Biomedical Research, 2012, 26(3): 200-210. doi: 10.7555/JBR.26.20110054